Strata Oncology is a precision oncology company based in Ann Arbor, Mich., focused on expanding a comprehensive genomic and transcriptomic profiling platform. The platform integrates comprehensive genomic profiling with highly quantitative RNA expression profiling to deliver molecular insights from a single, minute tumor tissue specimen. Strata offers a portfolio of treatment selection tests for solid tumors and is developing a personalized minimal residual disease (MRD) assay for early-stage cancers. The company is also advancing a pipeline of novel RNA-based treatment selection tests for solid tumors. Financially, Strata closed a $90M Series C and has raised over $130M in total since inception. The company is led by co-founder and CEO Dan Rhodes, Ph.D. Strata Oncology is an Ann Arbor, Mich.-based precision oncology platform that systematizes tumor molecular profiling and precision therapy trials across a network of health systems and pharma partners. The company integrates molecular profiling and precision therapy trials with routine care to enable system-wide precision oncology programs and provide a mechanism for rapid, predictable enrollment in precision therapy trials. Strata offers a tumor molecular profiling assay, StrataNGS, and develops clinical-genomic data and software solutions to streamline health system workflows. The company plans to expand its Strata Precision Oncology Network of adopting health systems, further develop its clinical-genomic data and software, and submit StrataNGS for FDA approval. It also intends to launch the PATH master therapeutic protocol to support rapid and cost-effective indication expansion studies for on-market drugs. Strata is led by CEO Dan Rhodes, PhD, and recently completed a significant Series B financing. Strata Oncology provides tumor sequencing to advanced cancer patients and maintains a portfolio of matching clinical trials. The company completed a $12M Series A financing to accelerate development of its tumor sequencing operation and to implement the Strata Trial, a nationwide effort to substantially increase enrollments in precision medicine clinical trials. It is based in Ann Arbor, Mich. Strata's core offering pairs next-generation sequencing-based tumor profiling with trial matching to connect patients to precision medicine studies. The company has a strategic partnership with Thermo Fisher Scientific, which will serve as technology provider and supply Ion S5 XL systems, AmpliSeq technology, and Oncomine assays. Strata was co-founded by Dan Rhodes (CEO), oncologist Keith Flaherty, M.D., and pathologist Scott Tomlins, M.D., Ph.D.

Total raised

$128M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2021